{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:51:02Z","timestamp":1792803062546,"version":"4.5.0"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Aging"],"DOI":"10.1038\/s43587-025-01029-3","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:01:47Z","timestamp":1766138507000},"page":"56-67","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-3309","authenticated-orcid":false,"given":"Marwan N.","family":"Sabbagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-5632","authenticated-orcid":false,"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-6224","authenticated-orcid":false,"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4996-1630","authenticated-orcid":false,"given":"Michael T.","family":"Heneka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte Bjerre","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-4708","authenticated-orcid":false,"given":"Mal\u00fa G\u00e1mez","family":"Tansey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6688-8127","authenticated-orcid":false,"given":"Daniel J.","family":"Drucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"1029_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bmcl.2018.11.034","volume":"29","author":"PV Fish","year":"2019","unstructured":"Fish, P. V., Steadman, D., Bayle, E. D. & Whiting, P. New approaches for the treatment of Alzheimer\u2019s disease. Bioorg. Med. Chem. Lett. 29, 125\u2013133 (2019).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1029_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ni.3102","volume":"16","author":"MT Heneka","year":"2015","unstructured":"Heneka, M. T., Golenbock, D. T. & Latz, E. Innate immunity in Alzheimer\u2019s disease. Nat. Immunol. 16, 229\u2013236 (2015).","journal-title":"Nat. Immunol."},{"key":"1029_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.776847","volume":"9","author":"Z Ou","year":"2021","unstructured":"Ou, Z. et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019. Front. Public Health 9, 776847 (2021).","journal-title":"Front. Public Health"},{"key":"1029_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130\u2013133 (2006).","journal-title":"Science"},{"key":"1029_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41582-021-00549-x","volume":"17","author":"BM Bettcher","year":"2021","unstructured":"Bettcher, B. M., Tansey, M. G., Doroth\u00e9e, G. & Heneka, M. T. Peripheral and central immune system crosstalk in Alzheimer disease\u2014a research prospectus. Nat. Rev. Neurol. 17, 689\u2013701 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"1029_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0039-1678581","volume":"39","author":"A Atri","year":"2019","unstructured":"Atri, A. Current and future treatments in Alzheimer\u2019s disease. Semin. Neurol. 39, 227\u2013240 (2019).","journal-title":"Semin. Neurol."},{"key":"1029_CR7","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3390\/medicina59061084","volume":"59","author":"AB Reiss","year":"2023","unstructured":"Reiss, A. B. et al. Alzheimer\u2019s disease treatment: the search for a breakthrough. Medicina 59, 1084 (2023).","journal-title":"Medicina"},{"key":"1029_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"1029_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1029_CR10","first-page":"e12465","volume":"10","author":"J Cummings","year":"2024","unstructured":"Cummings, J. et al. Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimers Dement. 10, e12465 (2024).","journal-title":"Alzheimers Dement."},{"key":"1029_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01183-8","author":"DJ Drucker","year":"2025","unstructured":"Drucker, D. J. GLP-1-based therapies for diabetes, obesity and beyond. Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/s41573-025-01183-8 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1029_CR12","first-page":"146","volume":"64","author":"A Alzheimer","year":"1907","unstructured":"Alzheimer, A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. 64, 146\u2013148 (1907).","journal-title":"Allg. Z. Psychiatr."},{"key":"1029_CR13","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","volume":"110","author":"RC Paolicelli","year":"2022","unstructured":"Paolicelli, R. C. et al. Microglia states and nomenclature: a field at its crossroads. Neuron 110, 3458\u20133483 (2022).","journal-title":"Neuron"},{"key":"1029_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712\u2013716 (2016).","journal-title":"Science"},{"key":"1029_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature25158","volume":"552","author":"C Venegas","year":"2017","unstructured":"Venegas, C. et al. Microglia-derived ASC specks cross-seed amyloid-\u03b2 in Alzheimer\u2019s disease. Nature 552, 355\u2013361 (2017).","journal-title":"Nature"},{"key":"1029_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising, C. et al. NLRP3 inflammasome activation drives tau pathology. Nature 575, 669\u2013673 (2019).","journal-title":"Nature"},{"key":"1029_CR17","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.neuron.2021.12.016","volume":"110","author":"F Brosseron","year":"2022","unstructured":"Brosseron, F. et al. Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer\u2019s disease. Neuron 110, 1009\u20131022 (2022).","journal-title":"Neuron"},{"key":"1029_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0353-3","volume":"10","author":"F Brosseron","year":"2018","unstructured":"Brosseron, F. et al. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer\u2019s disease. Alzheimers Res. Ther. 10, 25 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"1029_CR19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","volume":"17","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat. Rev. Neurol. 17, 580\u2013589 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"1029_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481\u2013487 (2017).","journal-title":"Nature"},{"key":"1029_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s41593-021-00905-6","volume":"24","author":"P Hasel","year":"2021","unstructured":"Hasel, P., Rose, I. V. L., Sadick, J. S., Kim, R. D. & Liddelow, S. A. Neuroinflammatory astrocyte subtypes in the mouse brain. Nat. Neurosci. 24, 1475\u20131487 (2021).","journal-title":"Nat. Neurosci."},{"key":"1029_CR22","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.4049\/jimmunol.2100737","volume":"209","author":"B Altendorfer","year":"2022","unstructured":"Altendorfer, B. et al. Transcriptomic profiling identifies CD8+ T cells in the brain of aged and Alzheimer\u2019s disease transgenic mice as tissue-resident memory T cells. J. Immunol. 209, 1272\u20131285 (2022).","journal-title":"J. Immunol."},{"key":"1029_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00627-2","volume":"18","author":"KA Walker","year":"2023","unstructured":"Walker, K. A. et al. The role of peripheral inflammatory insults in Alzheimer\u2019s disease: a review and research roadmap. Mol. Neurodegener. 18, 37 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1029_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0301-0082(00)00068-X","volume":"64","author":"E Farkas","year":"2001","unstructured":"Farkas, E. & Luiten, P. G. Cerebral microvascular pathology in aging and Alzheimer\u2019s disease. Prog. Neurobiol. 64, 575\u2013611 (2001).","journal-title":"Prog. Neurobiol."},{"key":"1029_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13061","volume":"32","author":"RA Fisher","year":"2022","unstructured":"Fisher, R. A., Miners, J. S. & Love, S. Pathological changes within the cerebral vasculature in Alzheimer\u2019s disease: new perspectives. Brain Pathol. 32, e13061 (2022).","journal-title":"Brain Pathol."},{"key":"1029_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.892899","volume":"16","author":"RL Wallings","year":"2022","unstructured":"Wallings, R. L. et al. WHOPPA enables parallel assessment of leucine-rich repeat kinase 2 and glucocerebrosidase enzymatic activity in Parkinson\u2019s disease monocytes. Front. Cell. Neurosci. 16, 892899 (2022).","journal-title":"Front. Cell. Neurosci."},{"key":"1029_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-024-07185-7","volume":"628","author":"MS Haney","year":"2024","unstructured":"Haney, M. S. et al. APOE4\/4 is linked to damaging lipid droplets in Alzheimer\u2019s disease microglia. Nature 628, 154\u2013161 (2024).","journal-title":"Nature"},{"key":"1029_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat. Genet. 54, 412\u2013436 (2022).","journal-title":"Nat. Genet."},{"key":"1029_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22491-8","volume":"12","author":"I de Rojas","year":"2021","unstructured":"de Rojas, I. et al. Common variants in Alzheimer\u2019s disease and risk stratification by polygenic risk scores. Nat. Commun. 12, 3417 (2021).","journal-title":"Nat. Commun."},{"key":"1029_CR30","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3233\/JAD-2010-100018","volume":"20","author":"J-C Lambert","year":"2010","unstructured":"Lambert, J.-C. et al. Implication of the immune system in Alzheimer\u2019s disease: evidence from genome-wide pathway analysis. J. Alzheimers Dis. 20, 1107\u20131118 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"1029_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204642","volume":"10","author":"N Garc\u00eda-Casares","year":"2021","unstructured":"Garc\u00eda-Casares, N. et al. Alzheimer\u2019s disease, mild cognitive impairment and Mediterranean diet. A systematic review and dose\u2013response meta-analysis. J. Clin. Med. 10, 4642 (2021).","journal-title":"J. Clin. Med."},{"key":"1029_CR32","doi-asserted-by":"publisher","first-page":"e2920","DOI":"10.1212\/WNL.0000000000012067","volume":"96","author":"T Ballarini","year":"2021","unstructured":"Ballarini, T. et al. Mediterranean diet, Alzheimer disease biomarkers and brain atrophy in old age. Neurology 96, e2920\u2013e2932 (2021).","journal-title":"Neurology"},{"key":"1029_CR33","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2016.1948","volume":"73","author":"PK Crane","year":"2016","unstructured":"Crane, P. K. et al. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurol. 73, 1062\u20131069 (2016).","journal-title":"JAMA Neurol."},{"key":"1029_CR34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3233\/JAD-220069","volume":"87","author":"A Graham","year":"2022","unstructured":"Graham, A., Livingston, G., Purnell, L. & Huntley, J. Mild traumatic brain injuries and future risk of developing Alzheimer\u2019s disease: systematic review and meta-analysis. J. Alzheimers Dis. 87, 969\u2013979 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"1029_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-161141","volume":"58","author":"C Jiang","year":"2017","unstructured":"Jiang, C., Li, G., Huang, P., Liu, Z. & Zhao, B. The gut microbiota and Alzheimer\u2019s disease. J. Alzheimers Dis. 58, 1\u201315 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"1029_CR36","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1073\/pnas.1222878110","volume":"110","author":"J Seok","year":"2013","unstructured":"Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507\u20133512 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1029_CR37","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1172\/JCI97233","volume":"127","author":"DJ Drucker","year":"2017","unstructured":"Drucker, D. J., Habener, J. F. & Holst, J. J. Discovery, characterization, and clinical development of the glucagon-like peptides. J. Clin. Invest. 127, 4217\u20134227 (2017).","journal-title":"J. Clin. Invest."},{"key":"1029_CR38","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.cmet.2019.08.009","volume":"30","author":"Y Song","year":"2019","unstructured":"Song, Y. et al. Gut-proglucagon-derived peptides are essential for regulating glucose homeostasis in mice. Cell Metab. 30, 976\u2013986 (2019).","journal-title":"Cell Metab."},{"key":"1029_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/379069a0","volume":"379","author":"MD Turton","year":"1996","unstructured":"Turton, M. D. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69\u201372 (1996).","journal-title":"Nature"},{"key":"1029_CR40","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher, A. et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Invest. 124, 4473\u20134488 (2014).","journal-title":"J. Clin. Invest."},{"key":"1029_CR41","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","volume":"3","author":"DI Brierley","year":"2021","unstructured":"Brierley, D. I. et al. Central and peripheral GLP-1 systems independently suppress eating. Nat. Metab. 3, 258\u2013273 (2021).","journal-title":"Nat. Metab."},{"key":"1029_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0306-4522(96)00434-4","volume":"77","author":"PJ Larsen","year":"1997","unstructured":"Larsen, P. J., Tang-Christensen, M., Holst, J. J. & \u00d8rskov, C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77, 257\u2013270 (1997).","journal-title":"Neuroscience"},{"key":"1029_CR43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","author":"S Gabery","year":"2020","unstructured":"Gabery, S. et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.133429 (2020).","journal-title":"JCI Insight"},{"key":"1029_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103739","volume":"74","author":"J Ast","year":"2021","unstructured":"Ast, J., Broichhagen, J. & Hodson, D. J. Reagents and models for detecting endogenous GLP1R and GIPR. EBioMedicine 74, 103739 (2021).","journal-title":"EBioMedicine"},{"key":"1029_CR45","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","volume":"66","author":"DJ Drucker","year":"2023","unstructured":"Drucker, D. J. & Holst, J. J. The expanding incretin universe: from basic biology to clinical translation. Diabetologia 66, 1765\u20131779 (2023).","journal-title":"Diabetologia"},{"key":"1029_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","volume":"381","author":"JB Buse","year":"2013","unstructured":"Buse, J. B. et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381, 117\u2013124 (2013).","journal-title":"Lancet"},{"key":"1029_CR47","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley, R. E. et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 6, 275\u2013286 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1029_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol. Metab. 46, 101102 (2021).","journal-title":"Mol. Metab."},{"key":"1029_CR49","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653\u2013662 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1029_CR50","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc24-1533","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee, M. M. Y. et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care 48, 846\u2013859 (2025).","journal-title":"Diabetes Care"},{"key":"1029_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker, D. J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol. Metab. 57, 101351 (2022).","journal-title":"Mol. Metab."},{"key":"1029_CR52","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1029_CR53","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","volume":"19","author":"D Kellar","year":"2020","unstructured":"Kellar, D. & Craft, S. Brain insulin resistance in Alzheimer\u2019s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 19, 758\u2013766 (2020).","journal-title":"Lancet Neurol."},{"key":"1029_CR54","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/BF02658511","volume":"39","author":"L \u00d8rskov","year":"1996","unstructured":"\u00d8rskov, L. et al. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39, 1227\u20131232 (1996).","journal-title":"Diabetologia"},{"key":"1029_CR55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","volume":"42","author":"BA McLean","year":"2021","unstructured":"McLean, B. A. et al. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr. Rev. 42, 101\u2013132 (2021).","journal-title":"Endocr. Rev."},{"key":"1029_CR56","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2337\/dc19-1465","volume":"43","author":"N Wang","year":"2020","unstructured":"Wang, N. et al. Vasodilatory actions of glucagon-like peptide 1 are preserved in skeletal and cardiac muscle microvasculature but not in conduit artery in obese humans with vascular insulin resistance. Diabetes Care 43, 634\u2013642 (2020).","journal-title":"Diabetes Care"},{"key":"1029_CR57","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s42255-021-00363-1","volume":"3","author":"MQ Ludwig","year":"2021","unstructured":"Ludwig, M. Q. et al. A genetic map of the mouse dorsal vagal complex and its role in obesity. Nat. Metab. 3, 530\u2013545 (2021).","journal-title":"Nat. Metab."},{"key":"1029_CR58","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s42255-022-00657-y","volume":"4","author":"L Steuernagel","year":"2022","unstructured":"Steuernagel, L. et al. HypoMap\u2014a unified single-cell gene expression atlas of the murine hypothalamus. Nat. Metab. 4, 1402\u20131419 (2022).","journal-title":"Nat. Metab."},{"key":"1029_CR59","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cmet.2020.05.001","volume":"31","author":"K Timper","year":"2020","unstructured":"Timper, K. et al. GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function. Cell Metab. 31, 1189\u20131205 (2020).","journal-title":"Cell Metab."},{"key":"1029_CR60","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/j.cmet.2024.09.003","volume":"36","author":"B Chen","year":"2024","unstructured":"Chen, B. et al. GLP-1 programs the neurovascular landscape. Cell Metab. 36, 2173\u20132189 (2024).","journal-title":"Cell Metab."},{"key":"1029_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162587","volume":"11","author":"AKO Rode","year":"2022","unstructured":"Rode, A. K. O. et al. Induced human regulatory T cells express the glucagon-like peptide-1 receptor. Cells 11, 2587 (2022).","journal-title":"Cells"},{"key":"1029_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/en.2014-1675","volume":"156","author":"KM Heppner","year":"2015","unstructured":"Heppner, K. M. et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 156, 255\u2013267 (2015).","journal-title":"Endocrinology"},{"key":"1029_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08504-8","author":"JA Tadross","year":"2025","unstructured":"Tadross, J. A. et al. A comprehensive spatio-cellular map of the human hypothalamus. Nature https:\/\/doi.org\/10.1038\/s41586-024-08504-8 (2025).","journal-title":"Nature"},{"key":"1029_CR64","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41586-021-04369-3","volume":"603","author":"AC Yang","year":"2022","unstructured":"Yang, A. C. et al. A human brain vascular atlas reveals diverse mediators of Alzheimer\u2019s risk. Nature 603, 885\u2013892 (2022).","journal-title":"Nature"},{"key":"1029_CR65","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jalz.2013.12.007","volume":"10","author":"K Talbot","year":"2014","unstructured":"Talbot, K. & Wang, H.-Y. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer\u2019s disease. Alzheimers Dement. 10, S12\u2013S25 (2014).","journal-title":"Alzheimers Dement."},{"key":"1029_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120074","volume":"10","author":"J Hakon","year":"2015","unstructured":"Hakon, J., Ruscher, K., Romner, B. & Tomasevic, G. Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury. PLoS ONE 10, e0120074 (2015).","journal-title":"PLoS ONE"},{"key":"1029_CR67","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s12035-016-9798-1","volume":"54","author":"C Zanotto","year":"2017","unstructured":"Zanotto, C. et al. Exendin-4 reverses biochemical and functional alterations in the blood\u2013brain and blood\u2013CSF barriers in diabetic rats. Mol. Neurobiol. 54, 2154\u20132166 (2017).","journal-title":"Mol. Neurobiol."},{"key":"1029_CR68","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00125-022-05730-5","volume":"65","author":"J Bailey","year":"2022","unstructured":"Bailey, J. et al. GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes. Diabetologia 65, 1541\u20131554 (2022).","journal-title":"Diabetologia"},{"key":"1029_CR69","doi-asserted-by":"publisher","first-page":"943","DOI":"10.14336\/AD.2021.1029","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Blocking C3d+\/GFAP+ A1 astrocyte conversion with semaglutide attenuates blood\u2013brain barrier disruption in mice after ischemic stroke. Aging Dis. 13, 943\u2013959 (2022).","journal-title":"Aging Dis."},{"key":"1029_CR70","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1007\/s12035-022-02811-9","volume":"59","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. GLP-1R agonist exendin-4 protects against hemorrhagic transformation induced by rtPA after ischemic stroke via the Wnt\/\u03b2-catenin signaling pathway. Mol. Neurobiol. 59, 3649\u20133664 (2022).","journal-title":"Mol. Neurobiol."},{"key":"1029_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1638-6","volume":"16","author":"Y Shan","year":"2019","unstructured":"Shan, Y. et al. The glucagon-like peptide-1 receptor agonist reduces inflammation and blood\u2013brain barrier breakdown in an astrocyte-dependent manner in experimental stroke. J. Neuroinflammation 16, 242 (2019).","journal-title":"J. Neuroinflammation"},{"key":"1029_CR72","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2022.06.002","volume":"34","author":"M Imbernon","year":"2022","unstructured":"Imbernon, M. et al. Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. Cell Metab. 34, 1054\u20131063 (2022).","journal-title":"Cell Metab."},{"key":"1029_CR73","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/ijo.2015.136","volume":"39","author":"M Christensen","year":"2015","unstructured":"Christensen, M. et al. Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. Int. J. Obes. 39, 1651\u20131654 (2015).","journal-title":"Int. J. Obes."},{"key":"1029_CR74","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00724-y","author":"J West","year":"2025","unstructured":"West, J. et al. Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: a narrative review. Neurol. Ther. https:\/\/doi.org\/10.1007\/s40120-025-00724-y (2025).","journal-title":"Neurol. Ther."},{"key":"1029_CR75","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.2147\/DMSO.S375559","volume":"15","author":"M Dong","year":"2022","unstructured":"Dong, M., Wen, S. & Zhou, L. The relationship between the blood\u2013brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium\u2013glucose cotransporter-2 inhibitors. Diabetes Metab. Syndr. Obes. 15, 2583\u20132597 (2022).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"1029_CR76","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2023.2292461","volume":"12","author":"EM Rhea","year":"2024","unstructured":"Rhea, E. M. et al. Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases. Tissue Barriers 12, 2292461 (2024).","journal-title":"Tissue Barriers"},{"key":"1029_CR77","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/s42255-025-01295-w","volume":"7","author":"CM Liu","year":"2025","unstructured":"Liu, C. M. et al. GIPR-Ab\/GLP-1 peptide\u2013antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice. Nat. Metab. 7, 1266\u20131281 (2025).","journal-title":"Nat. Metab."},{"key":"1029_CR78","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.2337\/diabetes.53.9.2492","volume":"53","author":"LL Baggio","year":"2004","unstructured":"Baggio, L. L., Huang, Q., Brown, T. J. & Drucker, D. J. A recombinant human glucagon-like peptide (GLP)-1\u2013albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53, 2492\u20132500 (2004).","journal-title":"Diabetes"},{"key":"1029_CR79","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/STROKEAHA.121.037775","volume":"53","author":"WD Strain","year":"2022","unstructured":"Strain, W. D. et al. Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6. Stroke 53, 2749\u20132757 (2022).","journal-title":"Stroke"},{"key":"1029_CR80","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2213-8587(19)30423-1","volume":"8","author":"HC Gerstein","year":"2020","unstructured":"Gerstein, H. C. et al. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes Endocrinol. 8, 106\u2013114 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1029_CR81","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm919","volume":"9","author":"MJ During","year":"2003","unstructured":"During, M. J. et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9, 1173\u20131179 (2003).","journal-title":"Nat. Med."},{"key":"1029_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01180-z","volume":"9","author":"J-S Park","year":"2021","unstructured":"Park, J.-S. et al. Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer\u2019s disease. Acta Neuropathol. Commun. 9, 78 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1029_CR83","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s43587-025-00869-3","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice. Nat. Aging 5, 1097\u20131113 (2025).","journal-title":"Nat. Aging"},{"key":"1029_CR84","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3233\/JAD-143090","volume":"46","author":"HH Hansen","year":"2015","unstructured":"Hansen, H. H. et al. The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer\u2019s disease. J. Alzheimers Dis. 46, 877\u2013888 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"1029_CR85","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.brainres.2015.12.052","volume":"1634","author":"HH Hansen","year":"2016","unstructured":"Hansen, H. H. et al. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Res. 1634, 158\u2013170 (2016).","journal-title":"Brain Res."},{"key":"1029_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158205","volume":"11","author":"HH Hansen","year":"2016","unstructured":"Hansen, H. H. et al. Long-term treatment with liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has no effect on \u03b2-amyloid plaque load in two transgenic APP\/PS1 mouse models of Alzheimer\u2019s disease. PLoS ONE 11, e0158205 (2016).","journal-title":"PLoS ONE"},{"key":"1029_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102019","volume":"89","author":"L Forny Germano","year":"2024","unstructured":"Forny Germano, L. et al. The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice. Mol. Metab. 89, 102019 (2024).","journal-title":"Mol. Metab."},{"key":"1029_CR88","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun, S. P. et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat. Med. 24, 931\u2013938 (2018).","journal-title":"Nat. Med."},{"key":"1029_CR89","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s11011-017-0059-4","volume":"32","author":"ARC Barreto-Vianna","year":"2017","unstructured":"Barreto-Vianna, A. R. C., Aguila, M. B. & Mandarim-de-Lacerda, C. A. Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation. Metab. Brain Dis. 32, 1735\u20131745 (2017).","journal-title":"Metab. Brain Dis."},{"key":"1029_CR90","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5607\/en.2017.26.4.227","volume":"26","author":"S Kim","year":"2017","unstructured":"Kim, S. et al. Anti-inflammatory effect of glucagon like peptide-1 receptor agonist, exendin-4, through modulation of IB1\/JIP1 expression and JNK signaling in stroke. Exp. Neurobiol. 26, 227\u2013239 (2017).","journal-title":"Exp. Neurobiol."},{"key":"1029_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111529","volume":"542","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer\u2019s disease by suppressing NLRP2 activation in astrocytes. Mol. Cell. Endocrinol. 542, 111529 (2022).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1029_CR92","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3233\/JAD-190237","volume":"70","author":"M Bomba","year":"2019","unstructured":"Bomba, M. et al. Exenatide reverts the high-fat-diet-induced impairment of BDNF signaling and inflammatory response in an animal model of Alzheimer\u2019s disease. J. Alzheimers Dis. 70, 793\u2013810 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"1029_CR93","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang, L., Zhang, L., Li, L. & H\u00f6lscher, C. Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease. J. Parkinsons Dis. 9, 157\u2013171 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"1029_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109653","volume":"115","author":"M-H Lin","year":"2023","unstructured":"Lin, M.-H. et al. The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4. Int. Immunopharmacol. 115, 109653 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"1029_CR95","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/cns.13791","volume":"28","author":"S Song","year":"2022","unstructured":"Song, S. et al. Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway. CNS Neurosci. Ther. 28, 422\u2013434 (2022).","journal-title":"CNS Neurosci. Ther."},{"key":"1029_CR96","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/oby.22666","volume":"28","author":"T Liao","year":"2020","unstructured":"Liao, T. et al. Liraglutide lowers body weight set point in DIO rats and its relationship with hypothalamic microglia activation. Obesity 28, 122\u2013131 (2020).","journal-title":"Obesity"},{"key":"1029_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173581","volume":"887","author":"J Huang","year":"2020","unstructured":"Huang, J. et al. Glucagon-like peptide-1 cleavage product GLP-1(9\u201336) reduces neuroinflammation from stroke via the activation of insulin-like growth factor 1 receptor in astrocytes. Eur. J. Pharmacol. 887, 173581 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"1029_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039656","volume":"7","author":"H-J Huang","year":"2012","unstructured":"Huang, H.-J. et al. Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection. PLoS ONE 7, e39656 (2012).","journal-title":"PLoS ONE"},{"key":"1029_CR99","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi, S. H. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther. Adv. Endocrinol. Metab. 15, 20420188231222367 (2024).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"1029_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.903455","volume":"14","author":"Y Sun","year":"2022","unstructured":"Sun, Y., Koyama, Y. & Shimada, S. Inflammation from peripheral organs to the brain: how does systemic inflammation cause neuroinflammation? Front. Aging Neurosci. 14, 903455 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"1029_CR101","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","volume":"36","author":"CK Wong","year":"2024","unstructured":"Wong, C. K. et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 36, 130\u2013143 (2024).","journal-title":"Cell Metab."},{"key":"1029_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01375-3","author":"J Deanfield","year":"2025","unstructured":"Deanfield, J. et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(25)01375-3 (2025).","journal-title":"Lancet"},{"key":"1029_CR103","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1126\/science.adn4128","volume":"385","author":"DJ Drucker","year":"2024","unstructured":"Drucker, D. J. The benefits of GLP-1 drugs beyond obesity. Science 385, 258\u2013260 (2024).","journal-title":"Science"},{"key":"1029_CR104","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/jgs.18306","volume":"71","author":"H Tang","year":"2023","unstructured":"Tang, H. et al. Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies. J. Am. Geriatr. Soc. 71, 2096\u20132106 (2023).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1029_CR105","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3233\/JAD-180808","volume":"66","author":"J Bohlken","year":"2018","unstructured":"Bohlken, J., Jacob, L. & Kostev, K. Association between the use of antihyperglycemic drugs and dementia risk: a case\u2013control study. J. Alzheimers Dis. 66, 725\u2013732 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"1029_CR106","first-page":"e12268","volume":"8","author":"CH N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard, C. H. et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement. 8, e12268 (2022).","journal-title":"Alzheimers Dement."},{"key":"1029_CR107","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-19-0259","volume":"181","author":"IK Wium-Andersen","year":"2019","unstructured":"Wium-Andersen, I. K., Osler, M., J\u00f8rgensen, M. B., Rungby, J. & Wium-Andersen, M. K. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case\u2013control study. Eur. J. Endocrinol. 181, 499\u2013507 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"1029_CR108","first-page":"e12139","volume":"7","author":"B Zhou","year":"2021","unstructured":"Zhou, B. et al. Association between exenatide use and incidence of Alzheimer\u2019s disease. Alzheimers Dement. 7, e12139 (2021).","journal-title":"Alzheimers Dement."},{"key":"1029_CR109","doi-asserted-by":"publisher","unstructured":"Williams, G. Pre-diagnosis observational and prescription history associated with Alzheimer\u2019s disease incidence. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2024.07.17.24310553 (2024).","DOI":"10.1101\/2024.07.17.24310553"},{"key":"1029_CR110","doi-asserted-by":"publisher","DOI":"10.1177\/1533317519899546","volume":"35","author":"H Akimoto","year":"2020","unstructured":"Akimoto, H. et al. Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. Am. J. Alzheimers Dis. Other Demen. 35, 1533317519899546 (2020).","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"1029_CR111","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 20, 8661\u20138672 (2024).","journal-title":"Alzheimers Dement."},{"key":"1029_CR112","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251351329","author":"W Wang","year":"2025","unstructured":"Wang, W. et al. Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: a real-world target trial emulation study. J. Alzheimers Dis. https:\/\/doi.org\/10.1177\/13872877251351329 (2025).","journal-title":"J. Alzheimers Dis."},{"key":"1029_CR113","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamaneurol.2025.0360","volume":"82","author":"A Seminer","year":"2025","unstructured":"Seminer, A. et al. Cardioprotective glucose-lowering agents and dementia risk: a systematic review and meta-analysis. JAMA Neurol. 82, 450\u2013460 (2025).","journal-title":"JAMA Neurol."},{"key":"1029_CR114","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca, M. P. et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 405, 1580\u20131593 (2025).","journal-title":"Lancet"},{"key":"1029_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01573-x","volume":"16","author":"I Koychev","year":"2024","unstructured":"Koychev, I. et al. Inflammatory proteins associated with Alzheimer\u2019s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial. Alzheimers Res. Ther. 16, 212 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"1029_CR116","first-page":"111","volume":"13","author":"PJ Kueck","year":"2023","unstructured":"Kueck, P. J., Morris, J. K. & Stanford, J. A. Current perspectives: obesity and neurodegeneration\u2014links and risks. Degener. Neurol. Neuromuscul. Dis. 13, 111\u2013129 (2023).","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"1029_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113537","volume":"143","author":"N Siddeeque","year":"2024","unstructured":"Siddeeque, N. et al. Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study. Int. Immunopharmacol. 143, 113537 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"1029_CR118","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","volume":"44","author":"F Vadini","year":"2020","unstructured":"Vadini, F. et al. Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. Int. J. Obes. 44, 1254\u20131263 (2020).","journal-title":"Int. J. Obes."},{"key":"1029_CR119","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","volume":"19","author":"T Cukierman-Yaffe","year":"2020","unstructured":"Cukierman-Yaffe, T. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 19, 582\u2013590 (2020).","journal-title":"Lancet Neurol."},{"key":"1029_CR120","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020734","volume":"10","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. Activation of glucagon-like peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway. J. Am. Heart Assoc. 10, e020734 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"1029_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17718-y","volume":"7","author":"M Gejl","year":"2017","unstructured":"Gejl, M. et al. Blood\u2013brain glucose transfer in Alzheimer\u2019s disease: effect of GLP-1 analog treatment. Sci. Rep. 7, 17490 (2017).","journal-title":"Sci. Rep."},{"key":"1029_CR122","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2174\/1567205016666190913155950","volume":"16","author":"RJ Mullins","year":"2019","unstructured":"Mullins, R. J. et al. A pilot study of exenatide actions in Alzheimer\u2019s disease. Curr. Alzheimer Res. 16, 741\u2013752 (2019).","journal-title":"Curr. Alzheimer Res."},{"key":"1029_CR123","doi-asserted-by":"publisher","unstructured":"Edison, P. et al. Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-04106-7 (2025).","DOI":"10.1038\/s41591-025-04106-7"},{"key":"1029_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings, J. L. et al. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res. Ther. 17, 14 (2025).","journal-title":"Alzheimers Res. Ther."},{"key":"1029_CR125","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205079","volume":"102","author":"P Scheltens","year":"2024","unstructured":"Scheltens, P. et al. Baseline characteristics from evoke and evoke+: two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimer\u2019s disease (P11-9.013). Neurology 102, 3350 (2024).","journal-title":"Neurology"},{"key":"1029_CR126","unstructured":"Novo Norodisk A\/S. Novo Nordisk A\/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. globalnewswire.com https:\/\/www.globenewswire.com\/news-release\/2025\/11\/24\/3193328\/0\/en\/Novo-Nordisk-A-S-Evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-Alzheimer-s-disease-progression.html (2025)."},{"key":"1029_CR127","first-page":"e70076","volume":"11","author":"M Sabbagh","year":"2025","unstructured":"Sabbagh, M. et al. Safety considerations of semaglutide in the potential treatment of Alzheimer\u2019s disease: a pooled analysis of semaglutide in adults aged \u2265 65 years. Alzheimers Dement. 11, e70076 (2025).","journal-title":"Alzheimers Dement."},{"key":"1029_CR128","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","volume":"28","author":"J Nowell","year":"2023","unstructured":"Nowell, J., Blunt, E. & Edison, P. Incretin and insulin signaling as novel therapeutic targets for Alzheimer\u2019s and Parkinson\u2019s disease. Mol. Psychiatry 28, 217\u2013229 (2023).","journal-title":"Mol. Psychiatry"},{"key":"1029_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073812","volume":"25","author":"K Kalinderi","year":"2024","unstructured":"Kalinderi, K., Papaliagkas, V. & Fidani, L. GLP-1 receptor agonists: a new treatment in Parkinson\u2019s disease. Int. J. Mol. Sci. 25, 3812 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1029_CR130","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jnc.13736","volume":"139","author":"J Jalewa","year":"2016","unstructured":"Jalewa, J., Sharma, M. K. & H\u00f6lscher, C. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells. J. Neurochem. 139, 55\u201367 (2016).","journal-title":"J. Neurochem."},{"key":"1029_CR131","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1523\/JNEUROSCI.23-07-02939.2003","volume":"23","author":"H Yamamoto","year":"2003","unstructured":"Yamamoto, H. et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J. Neurosci. 23, 2939\u20132946 (2003).","journal-title":"J. Neurosci."},{"key":"1029_CR132","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s13311-021-01018-5","volume":"18","author":"L-L Bu","year":"2021","unstructured":"Bu, L.-L. et al. Neuroprotection of exendin-4 by enhanced autophagy in a Parkinsonian rat model of \u03b1-synucleinopathy. Neurotherapeutics 18, 962\u2013978 (2021).","journal-title":"Neurotherapeutics"},{"key":"1029_CR133","first-page":"1818","volume":"18","author":"H-Y Yu","year":"2023","unstructured":"Yu, H.-Y. et al. Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson\u2019s disease. Neural Regen. Res. 18, 1818\u20131826 (2023).","journal-title":"Neural Regen. Res."},{"key":"1029_CR134","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","volume":"71","author":"L Zhang","year":"2018","unstructured":"Zhang, L., Zhang, L., Li, L. & H\u00f6lscher, C. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model. Neuropeptides 71, 70\u201380 (2018).","journal-title":"Neuropeptides"},{"key":"1029_CR135","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3233\/JPD-229002","volume":"12","author":"K McFarthing","year":"2022","unstructured":"McFarthing, K. et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2022 update. J. Parkinsons Dis. 12, 1073\u20131082 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"1029_CR136","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664\u20131675 (2017).","journal-title":"Lancet"},{"key":"1029_CR137","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner, W. G. et al. Trial of lixisenatide in early Parkinson\u2019s disease. N. Engl. J. Med. 390, 1176\u20131185 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1029_CR138","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam, N. et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405, 627\u2013636 (2025).","journal-title":"Lancet"},{"key":"1029_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105059","volume":"25","author":"A Motataianu","year":"2024","unstructured":"Motataianu, A. et al. Exploring the role of metabolic hormones in amyotrophic lateral sclerosis. Int. J. Mol. Sci. 25, 5059 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1029_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96418-0","volume":"11","author":"A Keerie","year":"2021","unstructured":"Keerie, A. et al. The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS. Sci. Rep. 11, 17027 (2021).","journal-title":"Sci. Rep."},{"key":"1029_CR141","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/21678421.2024.2446847","volume":"26","author":"K Stolwyk","year":"2025","unstructured":"Stolwyk, K. & Lee, I. Rapid progression of amyotrophic lateral sclerosis after initiation of GLP-1 agonist: a case report. Amyotroph. Lateral Scler. Frontotemporal Degener. 26, 382\u2013384 (2025).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"1029_CR142","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. 31, 951\u2013962 (2025).","journal-title":"Nat. Med."},{"key":"1029_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","volume":"182","author":"G Bendotti","year":"2022","unstructured":"Bendotti, G. et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol. Res. 182, 106320 (2022).","journal-title":"Pharmacol. Res."},{"key":"1029_CR144","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cmet.2023.12.018","volume":"36","author":"DJ Drucker","year":"2024","unstructured":"Drucker, D. J. Prevention of cardiorenal complications in people with type 2 diabetes and obesity. Cell Metab. 36, 338\u2013353 (2024).","journal-title":"Cell Metab."},{"key":"1029_CR145","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker, D. J. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care 47, 1873\u20131888 (2024).","journal-title":"Diabetes Care"},{"key":"1029_CR146","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jama.2025.14392","volume":"334","author":"MJ Gonzalez-Rellan","year":"2025","unstructured":"Gonzalez-Rellan, M. J. & Drucker, D. J. New molecules and indications for GLP-1 medicines. JAMA 334, 1231\u20131234 (2025).","journal-title":"JAMA"}],"container-title":["Nature Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-01029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-01029-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-01029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:02:25Z","timestamp":1769000545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-01029-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":146,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1038\/s43587-025-01029-3","relation":{},"ISSN":["2662-8465"],"issn-type":[{"value":"2662-8465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.N.S. discloses ownership interest (stock or stock options) in Lighthouse Pharmaceuticals; he consults for Eisai, Lilly, NeuroTherapia, Signant Health, Novo Nordisk, Anavex Life Sciences, Alzheon, Cognito Therapeutics, GSK and AbbVie. M.N.S. is supported by the National Institutes of Health grants R01AG059008, R01AG073212 and P30AG072980, as well as by the Barrow Neurological Foundation. J.L.C. has provided consultation to Acadia Pharmaceuticals, Acumen Pharmaceuticals, ALZpath, Annovis, Aprinoia Therapeutics, Artery Therapeutics, Biogen, Biohaven, BioXcel, Bristol Myers Squibb, Eisai, Fosun, GAP Foundation, Green Valley, Janssen, Karuna, Kinoxis Therapeutics, Lighthouse Pharmaceuticals, Lilly, Lundbeck, LSP\/EQT Life Sciences, Mangrove Therapeutics, Merck, MoCA Cognition, New Amsterdam, Novo Nordisk, OptoCeutics, Otsuka, Oxford Brain Diagnostics, Praxis, Prothena, reMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, Sinaptica, T-Neuro, TrueBinding and Vaxxinity pharmaceutical, assessment and investment companies. J.L.C. is supported by the National Institute of General Medical Sciences (NIGMS) grant P20GM109025, National Institute on Aging (NIA) grants R35AG71476 and R25AG083721-01, National Institute of Neurological Disorders and Stroke (NINDS) grant RO1NS139383, the Alzheimer\u2019s Drug Discovery Foundation (ADDF), Ted and Maria Quirk Endowment, and Joy Chambers-Grundy Endowment. C.B. has received contract grant funding from Acadia Pharmaceuticals, Lundbeck, Takeda and Axovant pharmaceutical companies, as well as honoraria from Lundbeck, Lilly, Otsuka and Orion pharmaceutical companies. W.M.v.d.F. declares having research programs that have been funded by ZonMw, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland (Topsector Life Sciences & Health), Stichting Dioraphte, Gieskes-Strijbis Fonds, Stichting Equilibrio, Edwin Bouw Fonds, Pasman Stichting, Stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc., Novartis-NL, Life-MI, AVID, Roche BV, Eli Lilly-NL, Fujifilm, Eisai and Combinostics. W.M.v.d.F. holds the Pasman chair. W.M.v.d.F. is a recipient of ABOARD, which is a public\u2013private partnership receiving funding from ZonMw (#73305095007) and Health~Holland (Topsector Life Sciences & Health) (public\u2013private partnership allowance; #LSHM20106). W.M.v.d.F. is a recipient of TAP-dementia (\n                      \n                      ), which receives funding from ZonMw (#10510032120003). TAP-dementia receives cofinancing from Avid Radiopharmaceuticals and Amprion. All funding is paid to her institution. W.M.v.d.F. has been an invited speaker at Biogen MA Inc., Danone, Eisai, WebMD Neurology (Medscape), Novo Nordisk, Springer Healthcare and European Brain Council. All funding is paid to her institution. W.M.v.d.F. is a consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc. and Eisai. All funding is paid to her institution. W.M.v.d.F. participated in the advisory boards of Biogen MA Inc., Roche and Eli Lilly. W.M.v.d.F. is a member of the steering committee of evoke\/evoke+ (Novo Nordisk). All funding is paid to her institution. W.M.v.d.F. is a member of the steering committee of PAVE and Think Brain Health. W.M.v.d.F. was an associate editor of\n                      Alzheimer\u2019s Research & Therapy\n                      in 2020\/2021 and is an associate editor at\n                      Brain\n                      . M.T.H. serves on the science advisory board of the UK Dementia Research Institute at Imperial College London, Life and Health Sciences Research Institute of the University of Minho School of Medicine, the Lyon Neuroscience Research Center, Alector, Muna Therapeutics and T3D Therapeutics. He has received speaking honoraria from Novo Nordisk, Novartis, Biogen and Eli Lilly. J.J.H. consults for Novo Nordisk and is the founder of Antag Pharmaceuticals. L.B.K. is an employee and a minor employee related shareholder of Novo Nordisk A\/S. L.B.K. is an inventor on several patents related to GLP-1-based medicines and various uses of them. S.S. has provided consultation to Eisai, Biogen, Lilly, Roche, Genentech, Bolden, Novo Nordisk, Prothena, Acumen Pharmaceuticals, Labcorp, Alector, Corium, Kisbee, Neurophet, Icometrix and AbbVie. S.S. receives research support for clinical trials from Janssen, Lilly, Eisai, Genentech, Roche and Biogen. S.S. is an associate editor of the\n                      Journal of Prevention of Alzheimer\u2019s Disease\n                      and\n                      Alzheimer\u2019s and Dementia: Diagnosis, Assessment and Disease Monitoring\n                      . M.G.T. is supported by NINDS grant RF1NS128800, the Michael J. Fox Foundation for Parkinson\u2019s Research and the Parkinson\u2019s Foundation. She has provided consultation to INmune Bio, Merck, Calico, Forward Therapeutics, Jaya, SciNeuro, NysnoBio, Longevity Biotech, Sanofi, iMetabolic Pharma, Novo Nordisk and iMMvention. She serves on advisory boards for the Weston Family Foundation, the Medical and Scientific Advisory Group of the Alzheimer\u2019s Association, Longeveron and the Parkinson\u2019s Foundation. D.J.D. has been a supported speaker or consultant for AstraZeneca, Boehringer Ingelheim, Kallyope, Merck, Novo Nordisk and Pfizer, as well as receives grant support for preclinical studies from Amgen, Zealand Pharma and Eli Lilly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}